Promising results for breast cancer 'smart bomb' treatment

Phase III data have shown significantly increased survival in patients with HER2-positive breast cancer given a new type of drug.

Trastuzumab emtansine slows the progression of HER2-positive metastatic breast cancer | SCIENCE PHOTO LIBRARY
Trastuzumab emtansine slows the progression of HER2-positive metastatic breast cancer | SCIENCE PHOTO LIBRARY

Targeted treatment

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab (Herceptin) linked to the chemotherapy agent emtansine (DM1). It specifically targets HER2-positive cancers, not only inhibiting HER2 signalling but also releasing emtansine directly into the tumour cells (a so-called 'smart bomb' approach), thus sparing healthy cells the drug’s cytotoxic effects.

Increased survival

Investigators presented the results of the first phase III study of trastuzumab emtansine at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) earlier this month.

The EMILIA study enrolled 991 people with HER2-positive metastatic breast cancer that had progressed despite treatment with trastuzumab and a taxane. Patients were randomised to receive trastuzumab emtansine 3.6mg/kg every 3 weeks, or lapatinib 1.25g daily plus capecitabine 2g/m2 (on days 1–14) every 3 weeks until disease progression or unmanageable toxicity occurred.

Follow-up continued for a median of 12.9 months in the trastuzumab emtansine group and 12.4 months in the lapatinib plus capecitabine group.

The researchers found that patients who received the antibody-drug conjugate lived significantly longer without disease progression than those who received lapatinib plus capecitabine (median 9.6 months vs 6.4 months, p<0.0001). Trastuzumab emtansine was associated with a lower incidence of serious adverse events than lapatinib/capecitabine (40.8% vs 57%).

Data on overall survival are due to be released at a later date.

Ongoing studies

Two other phase III studies of trastuzumab emtansine are underway. MARIANNE is comparing the antibody-drug conjugate with two different dual therapy regimens in patients who have not yet received treatment for their metastatic disease. TH3RESA is comparing trastuzumab emtansine to the physician’s choice of treatment in patients who have already received trastuzumab and lapatinib.

The developer of trastuzumab emtansine, Roche, plans to submit the drug for regulatory approval this year.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases